Publication
Title
The challenge of new drug discovery for tuberculosis
Author
Abstract
Tuberculosis (TB) is more prevalent in the world today than at any other time in human history. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse strategies to survive in a variety of host lesions and to evade immune surveillance. A key question is how robust are our approaches to discovering new TB drugs, and what measures could be taken to reduce the long and protracted clinical development of new drugs. The emergence of multi-drug-resistant strains of M. tuberculosis makes the discovery of new molecular scaffolds a priority, and the current situation even necessitates the re-engineering and repositioning of some old drug families to achieve effective control. Whatever the strategy used, success will depend largely on our proper understanding of the complex interactions between the pathogen and its human host. In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients.
Language
English
Source (journal)
Nature. - London, 1869, currens
Publication
London : MacMillan , 2011
ISSN
0028-0836 [print]
1476-4687 [online]
DOI
10.1038/NATURE09657
Volume/pages
469 :7331 (2011) , p. 483-490
ISI
000286596500023
Full text (Publisher's DOI)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 28.02.2011
Last edited 25.05.2022
To cite this reference